GlobeNewswire: Algernon Pharmaceuticals Inc. Contains the last 10 of 270 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:00:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853408/0/en/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-U-S-Based-Seyltx-for-USD-2M-and-a-20-Equity-Position.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position2024-03-27T16:04:57Z<![CDATA[VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 (“Ifenprodil”) research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx. The Company previously announced on November 22, 2023 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.]]>https://www.globenewswire.com/news-release/2024/01/31/2820948/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-CKD.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD2024-01-31T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 201980043698.6 for its antifibrotic drug candidate NP-251 (Repirinast).]]>https://www.globenewswire.com/news-release/2024/01/11/2807778/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-in-Japan-for-Idiopathic-Pulmonary-Fibrosis.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis2024-01-11T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF). The Company was previously granted a patent for the treatment of IPF in Canada and has also filed corresponding patent applications in the U.S., Europe, and China.]]>https://www.globenewswire.com/news-release/2023/12/27/2801516/0/en/Algernon-Pharmaceuticals-Announces-Closing-of-Private-Placement.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Closing of Private Placement2023-12-27T21:01:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on December 12, 2023 and updated on December 27, 2023, for gross proceeds of $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.]]>https://www.globenewswire.com/news-release/2023/12/27/2801312/0/en/Algernon-Pharmaceuticals-Announces-Increase-to-Private-Placement.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Increase to Private Placement 2023-12-27T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.20 per Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on December 27, 2023.]]>https://www.globenewswire.com/news-release/2023/12/13/2795182/0/en/Algernon-Pharmaceuticals-Announces-Private-Placement.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Private Placement 2023-12-13T00:42:36Z<![CDATA[VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.20 per Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on December 20, 2023.]]>https://www.globenewswire.com/news-release/2023/11/30/2788453/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-and-NAFLD.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD2023-11-30T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).]]>https://www.globenewswire.com/news-release/2023/11/22/2784687/0/en/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-U-S-Based-Seyltx-for-USD-2M-and-a-20-Equity-Position.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position2023-11-22T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”) research program for USD $2M cash and a 20% common share equity position in Seyltx. The transaction is subject to certain conditions including, inter alia, Seyltx financing and the negotiation and execution of a definitive agreement, which is expected to occur within the next 90 days.]]>https://www.globenewswire.com/news-release/2023/11/08/2776069/0/en/Algernon-Pharmaceuticals-Receives-Japanese-Patent-Notice-of-Allowance-for-Treatment-of-NASH-with-Repirinast.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast2023-11-08T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).]]>https://www.globenewswire.com/news-release/2023/09/06/2738211/0/en/Algernon-Pharmaceuticals-Announces-Grant-of-U-S-Patent-for-Repirinast-in-NAFLD-and-NASH.html?f=22&fvtc=4&fvtv=43444Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH2023-09-06T11:00:00Z<![CDATA[VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the United States Patent and Trademark Office (USPTO), No. 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”]]>